Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 387

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease

Kuhl, D.E., Koeppe, R.A., Minoshima, S., Snyder, S.E., Ficaro, E.P., Foster, N.L., Frey, K.A., Kilbourn, M.R.·1999·Neurology

Abstract

OBJECTIVE: To validate an in vivo method for mapping acetylcholinesterase (AChE) activity in human brain, preparatory to monitoring inhibitor therapy in AD. BACKGROUND: AChE activity is decreased in postmortem AD brain. Lacking a reliable in vivo measure, little is known about central activity in early AD, when the disease is commonly targeted by AChE inhibitor drug therapy. METHODS: Intravenous N-[11C]methylpiperidin-4-yl propionate ([11C]PMP) served as an in vivo AChE substrate. AChE activity was defined using cerebral PET for tracer kinetic estimates of the local rate of [11C]PMP hydrolysis in 26 normal controls and 14 patients with AD. Eleven AD patients also had concomitant in vivo cerebral measures of vesicular acetylcholine transporter (cholinergic terminal) density and glucose metabolism. RESULTS: Cerebral AChE activity measures 1) were independent of changes in tracer delivery to cerebral cortex; 2) agreed with reported postmortem data concerning normal relative cerebral distributions, absence of large age-effect in normal aging, and deficits in AD; 3) correlated in AD cerebral cortex with concomitant in vivo measures of cholinergic terminal deficits, but not with metabolic deficits; and 4) agreed quantitatively with predicted level of cerebral AChE inhibition induced by physostimine. CONCLUSIONS: This in vivo PET method provided valid measures of central AChE activity in normal subjects and AD patients. Applied in early AD, it should facilitate inhibitor treatment by confirming central inhibition, optimizing drug dosage, identifying likely responders, and testing surrogate markers of therapeutic response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.52.4.691

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Research works printed but not linked: 5

  1. Geula C Mesulam M-M. Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. In: Terry RD Katzman R Bick KL eds. Alzheimer disease. New York: Raven Press 1994.
  2. 10.1002/(SICI)1098-2396(199602)22:2<123::AID-SYN5>3.0.CO;2-F · doi:10.1002/(sici)1098-2396(199602)22:2<123::aid-syn5>3.0.co;2-f
  3. Kuhl DE, Koeppe RA, Snyder SE, Minoshima S, Frey KA, Kilbourn MR. Mapping acetylcholinesterase in human brain using PET and N-[C-11]methylpiperidinyl propionate (PMP). J Nucl Med 1996;37 (5):21P.
  4. Hara M, Minoshima S, Foster NL, Kuhl DE. Is regional cerebral blood flow coupled with glucose metabolism in Alzheimer’s disease? J Nucl Med 1993;34 (5):116P.
  5. Friedland RP, Brun A, Budinger TF. Pathological and PET correlations in Alzheimer’s disease. Lancet 1985;1:228.

Cited by

See all 387

Metadata

Authors
Kuhl, D. E., Koeppe, R. A., Minoshima, S., Snyder, S. E., Ficaro, E. P., Foster, N. L., Frey, K. A., & Kilbourn, M. R.
Venue
Neurology
Published
1999-03
Volume
52
Issue
4
Pages
691-691
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2048755200
Cited by
387
References
36
FWCI
14.14
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease. https://app.cochat.ai/papers/10.1212/wnl.52.4.691
The paper
Kuhl, D. E., Koeppe, R. A., Minoshima, S., Snyder, S. E., Ficaro, E. P., Foster, N. L., Frey, K. A., & Kilbourn, M. R. (1999). In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease. Neurology. https://doi.org/10.1212/wnl.52.4.691

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.